The two components of Orkambi act separately to trigger a liver enzyme that decreases the therapy’s ability to fight cystic fibrosis, a study reported. Vertex Pharmaceuticals created Orkambi by combining ivacaftor and lumacaftor (VX-809). It addresses the underlying cause of the disease — a gene mutation that leads to a build-up of…
News
Abnormalities in continuous glucose monitoring (CGM) measures correlate with a decline in lung function in children and adolescents with cystic fibrosis (CF), a study suggests. The study, “Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline,” was published in the Journal of Cystic…
Bacteria can transmit memory across generations so their descendants will know how to attach themselves to surfaces and form communities called biofilms, a study reports. Researchers’ findings shed light on cystic fibrosis-related bacteria’s early steps in biofilm formation. These pathogens cause persistent airway infections in people with the disease. The…
The Cystic Fibrosis Foundation (CFF) has joined 70 other organizations in signing a letter opposing the latest version of the Right to Try Act, which the House passed recently. It would allow terminally ill Americans to try medicines that have passed Phase 1 of the U.S. Food and Drug Administration…
The U.S. Food and Drug Administration has granted Fast Track Designation to Proteostasis Therapeutics’ triple combo treatment program for cystic fibrosis. The program includes the company’s amplifier, corrector, and potentiator of the CFTR gene — a combination designed to overcome the impact of the mutations that cause CF. The…
AbbVie has opened applications for its 2018-2019 academic-year scholarships for undergraduate and graduate students with cystic fibrosis. The program awards $3,000 to 40 students, based on their academic excellence, creativity and community service. The 40 winners can also compete for a $25,000 special award in two categories — Thriving Undergraduate…
Almost everyone with cystic fibrosis or pulmonary fibrosis would like to have a remote monitoring device that allows them to keep tabs on their lung function at home, online surveys of the two patient groups indicate. PMD Healthcare said it conducted the surveys to learn CF and PF patients’ views on lung…
AB569, Arch Biopartners’ treatment candidate for bacterial infections in patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), and other respiratory conditions, has received a U.S. patent. The U.S. Patent and Trademark Office issued patent 9,925,206 to the University of Cincinnati, which granted Arch Biopartners an…
GeneFo has put together an updated 2018 guide on treatment options for people with cystic fibrosis (CF) after recent developments again focused attention on the high price tag of some of these medications and the difficulties patients face in accessing them. The guide includes information on financial and clinical resources to…
The Boomer Esiason Foundation (BEF) recently received a $50,000 grant from the Investors Bank and the Investors Foundation in recognition of the nonprofit’s 25 years of dedicated service to the cystic fibrosis (CF) community. The grant highlights the positive partnership built by Investors Bank and former…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.